Rotenone induces non-specific central nervous system and systemic toxicity.
Identifieur interne : 001356 ( PubMed/Corpus ); précédent : 001355; suivant : 001357Rotenone induces non-specific central nervous system and systemic toxicity.
Auteurs : Nicolas Lapointe ; Michel St-Hilaire ; Maria-Grazia Martinoli ; Julie Blanchet ; Peter Gould ; Claude Rouillard ; Francesca CicchettiSource :
- FASEB journal : official publication of the Federation of American Societies for Experimental Biology [ 1530-6860 ] ; 2004.
English descriptors
- KwdEn :
- Animals, Brain (drug effects), Brain (pathology), Disease Models, Animal, Dopamine (metabolism), Motor Activity (drug effects), Neurodegenerative Diseases (chemically induced), Neurodegenerative Diseases (pathology), Neurodegenerative Diseases (physiopathology), Neurons (drug effects), Neurons (pathology), Parkinson Disease, Secondary (chemically induced), Rats, Rotenone (toxicity).
- MESH :
- chemical , metabolism : Dopamine.
- chemically induced : Neurodegenerative Diseases, Parkinson Disease, Secondary.
- drug effects : Brain, Motor Activity, Neurons.
- pathology : Brain, Neurodegenerative Diseases, Neurons.
- physiopathology : Neurodegenerative Diseases.
- chemical , toxicity : Rotenone.
- Animals, Disease Models, Animal, Rats.
Abstract
We investigated the dopaminergic (DA) neuronal degeneration in animals subjected to systemic treatment of rotenone via subcutaneous delivery. Behavioral observations revealed a hypokinetic period in rats sacrificed at 3 and 5 days, and dystonic episodes in animals sacrificed at 8 days. Less than 20% of the total number of animals given rotenone depicted brain lesions after 8 days of treatment, as demonstrated by a significant loss of DA fibers in the striatum, but not of DA nigral neurons. Tyrosine hydroxylase-negative striatal territories were characterized by post-synaptic toxicity as demonstrated by a decreased number of interneurons labeled for choline acetyltransferase, NADPH-diaphorase, parvalbumin, and projection neurons labeled for calbindin and nerve growth factor inducible-B (NGFI-B). Post-synaptic neurodegeneration was demonstrated further by abundant striatal staining for Fluoro-Jade. Decrease in the nuclear orphan receptor Nurr1 expression was the only significant change observed at the level of the substantia nigra. Autopsy reports confirmed that animals suffered from severe digestion problems. These data suggest that hypokinesia observed between 3 and 5 days is the result of general health problems rather than a specific motor deficit associated to Parkinson's disease (PD) symptoms. Overall, the effects of rotenone toxicity are widespread, and subcutaneous administration of this toxin does not provide the neuropathological and behavioral basis for a relevant and reliable PD model.
DOI: 10.1096/fj.03-0677fje
PubMed: 14766796
Links to Exploration step
pubmed:14766796Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rotenone induces non-specific central nervous system and systemic toxicity.</title>
<author><name sortKey="Lapointe, Nicolas" sort="Lapointe, Nicolas" uniqKey="Lapointe N" first="Nicolas" last="Lapointe">Nicolas Lapointe</name>
<affiliation><nlm:affiliation>Centre de Recherche en Neurosciences, CHUL, Sainte-Foy, Québec, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="St Hilaire, Michel" sort="St Hilaire, Michel" uniqKey="St Hilaire M" first="Michel" last="St-Hilaire">Michel St-Hilaire</name>
</author>
<author><name sortKey="Martinoli, Maria Grazia" sort="Martinoli, Maria Grazia" uniqKey="Martinoli M" first="Maria-Grazia" last="Martinoli">Maria-Grazia Martinoli</name>
</author>
<author><name sortKey="Blanchet, Julie" sort="Blanchet, Julie" uniqKey="Blanchet J" first="Julie" last="Blanchet">Julie Blanchet</name>
</author>
<author><name sortKey="Gould, Peter" sort="Gould, Peter" uniqKey="Gould P" first="Peter" last="Gould">Peter Gould</name>
</author>
<author><name sortKey="Rouillard, Claude" sort="Rouillard, Claude" uniqKey="Rouillard C" first="Claude" last="Rouillard">Claude Rouillard</name>
</author>
<author><name sortKey="Cicchetti, Francesca" sort="Cicchetti, Francesca" uniqKey="Cicchetti F" first="Francesca" last="Cicchetti">Francesca Cicchetti</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:14766796</idno>
<idno type="pmid">14766796</idno>
<idno type="doi">10.1096/fj.03-0677fje</idno>
<idno type="wicri:Area/PubMed/Corpus">001356</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001356</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Rotenone induces non-specific central nervous system and systemic toxicity.</title>
<author><name sortKey="Lapointe, Nicolas" sort="Lapointe, Nicolas" uniqKey="Lapointe N" first="Nicolas" last="Lapointe">Nicolas Lapointe</name>
<affiliation><nlm:affiliation>Centre de Recherche en Neurosciences, CHUL, Sainte-Foy, Québec, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="St Hilaire, Michel" sort="St Hilaire, Michel" uniqKey="St Hilaire M" first="Michel" last="St-Hilaire">Michel St-Hilaire</name>
</author>
<author><name sortKey="Martinoli, Maria Grazia" sort="Martinoli, Maria Grazia" uniqKey="Martinoli M" first="Maria-Grazia" last="Martinoli">Maria-Grazia Martinoli</name>
</author>
<author><name sortKey="Blanchet, Julie" sort="Blanchet, Julie" uniqKey="Blanchet J" first="Julie" last="Blanchet">Julie Blanchet</name>
</author>
<author><name sortKey="Gould, Peter" sort="Gould, Peter" uniqKey="Gould P" first="Peter" last="Gould">Peter Gould</name>
</author>
<author><name sortKey="Rouillard, Claude" sort="Rouillard, Claude" uniqKey="Rouillard C" first="Claude" last="Rouillard">Claude Rouillard</name>
</author>
<author><name sortKey="Cicchetti, Francesca" sort="Cicchetti, Francesca" uniqKey="Cicchetti F" first="Francesca" last="Cicchetti">Francesca Cicchetti</name>
</author>
</analytic>
<series><title level="j">FASEB journal : official publication of the Federation of American Societies for Experimental Biology</title>
<idno type="eISSN">1530-6860</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Brain (drug effects)</term>
<term>Brain (pathology)</term>
<term>Disease Models, Animal</term>
<term>Dopamine (metabolism)</term>
<term>Motor Activity (drug effects)</term>
<term>Neurodegenerative Diseases (chemically induced)</term>
<term>Neurodegenerative Diseases (pathology)</term>
<term>Neurodegenerative Diseases (physiopathology)</term>
<term>Neurons (drug effects)</term>
<term>Neurons (pathology)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Rats</term>
<term>Rotenone (toxicity)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Neurodegenerative Diseases</term>
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term>
<term>Motor Activity</term>
<term>Neurons</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term>
<term>Neurodegenerative Diseases</term>
<term>Neurons</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Neurodegenerative Diseases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Rotenone</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Rats</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We investigated the dopaminergic (DA) neuronal degeneration in animals subjected to systemic treatment of rotenone via subcutaneous delivery. Behavioral observations revealed a hypokinetic period in rats sacrificed at 3 and 5 days, and dystonic episodes in animals sacrificed at 8 days. Less than 20% of the total number of animals given rotenone depicted brain lesions after 8 days of treatment, as demonstrated by a significant loss of DA fibers in the striatum, but not of DA nigral neurons. Tyrosine hydroxylase-negative striatal territories were characterized by post-synaptic toxicity as demonstrated by a decreased number of interneurons labeled for choline acetyltransferase, NADPH-diaphorase, parvalbumin, and projection neurons labeled for calbindin and nerve growth factor inducible-B (NGFI-B). Post-synaptic neurodegeneration was demonstrated further by abundant striatal staining for Fluoro-Jade. Decrease in the nuclear orphan receptor Nurr1 expression was the only significant change observed at the level of the substantia nigra. Autopsy reports confirmed that animals suffered from severe digestion problems. These data suggest that hypokinesia observed between 3 and 5 days is the result of general health problems rather than a specific motor deficit associated to Parkinson's disease (PD) symptoms. Overall, the effects of rotenone toxicity are widespread, and subcutaneous administration of this toxin does not provide the neuropathological and behavioral basis for a relevant and reliable PD model.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14766796</PMID>
<DateCreated><Year>2004</Year>
<Month>03</Month>
<Day>31</Day>
</DateCreated>
<DateCompleted><Year>2004</Year>
<Month>07</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-6860</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>6</Issue>
<PubDate><Year>2004</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title>
<ISOAbbreviation>FASEB J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Rotenone induces non-specific central nervous system and systemic toxicity.</ArticleTitle>
<Pagination><MedlinePgn>717-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We investigated the dopaminergic (DA) neuronal degeneration in animals subjected to systemic treatment of rotenone via subcutaneous delivery. Behavioral observations revealed a hypokinetic period in rats sacrificed at 3 and 5 days, and dystonic episodes in animals sacrificed at 8 days. Less than 20% of the total number of animals given rotenone depicted brain lesions after 8 days of treatment, as demonstrated by a significant loss of DA fibers in the striatum, but not of DA nigral neurons. Tyrosine hydroxylase-negative striatal territories were characterized by post-synaptic toxicity as demonstrated by a decreased number of interneurons labeled for choline acetyltransferase, NADPH-diaphorase, parvalbumin, and projection neurons labeled for calbindin and nerve growth factor inducible-B (NGFI-B). Post-synaptic neurodegeneration was demonstrated further by abundant striatal staining for Fluoro-Jade. Decrease in the nuclear orphan receptor Nurr1 expression was the only significant change observed at the level of the substantia nigra. Autopsy reports confirmed that animals suffered from severe digestion problems. These data suggest that hypokinesia observed between 3 and 5 days is the result of general health problems rather than a specific motor deficit associated to Parkinson's disease (PD) symptoms. Overall, the effects of rotenone toxicity are widespread, and subcutaneous administration of this toxin does not provide the neuropathological and behavioral basis for a relevant and reliable PD model.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lapointe</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Centre de Recherche en Neurosciences, CHUL, Sainte-Foy, Québec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>St-Hilaire</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Martinoli</LastName>
<ForeName>Maria-Grazia</ForeName>
<Initials>MG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Blanchet</LastName>
<ForeName>Julie</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gould</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rouillard</LastName>
<ForeName>Claude</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cicchetti</LastName>
<ForeName>Francesca</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2004</Year>
<Month>02</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>FASEB J</MedlineTA>
<NlmUniqueID>8804484</NlmUniqueID>
<ISSNLinking>0892-6638</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>03L9OT429T</RegistryNumber>
<NameOfSubstance UI="D012402">Rotenone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="Y">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012402" MajorTopicYN="N">Rotenone</DescriptorName>
<QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>2</Month>
<Day>10</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>7</Month>
<Day>16</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>2</Month>
<Day>10</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">14766796</ArticleId>
<ArticleId IdType="doi">10.1096/fj.03-0677fje</ArticleId>
<ArticleId IdType="pii">03-0677fje</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001356 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001356 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:14766796 |texte= Rotenone induces non-specific central nervous system and systemic toxicity. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:14766796" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |